Cytokine-Encapsulated Biodegradable Microspheres for Immune Therapy

References

• Arora A, Su G, Mathiowitz E, Reineke J, Chang AE, Sabel MS. 2006. Neoadjuvant intratumoral cytokine-loaded microspheres are superior to postoperative autologous cellular vaccines in generating systemic anti-tumor immunity. J Surg Oncol. 94(5):403–12.
   PubMed Web of Science ®Google Scholar
• Bakhru SH, Furtado S, Morello AP, Mathiowitz E. 2013. Oral delivery of proteins by biodegradable nanoparticles. Adv Drug Delivery Rev. 65(6):811–21.
   PubMed Web of Science ®Google Scholar
• Bhutiani N, Li Q, Anderson CD, Gallagher HC, De Jesus M, Singh R, Jala VR, Fraig M, Gu T, Egilmez NK. 2018. Enhanced gut barrier integrity sensitizes colon cancer to immune therapy. Oncoimmunology. 7(11):e1498438.
   PubMed Web of Science ®Google Scholar
• Cai DZ, Zeng C, Quan DP, Bu LS, Wang K, Lu HD, Li XF. 2007. Biodegradable chitosan scaffolds containing microspheres as carriers for controlled transforming growth factor-beta1 delivery for cartilage tissue engineering. Chin Med J (Engl). 120(3):197–203.
   PubMed Web of Science ®Google Scholar
• Chen L, Apte RN, Cohen S. 1997. Characterization of PLGA microspheres for the controlled delivery of IL-1 alpha for tumor immunotherapy. J Controlled Release. 43(2–3):261–72.
   Web of Science ®Google Scholar
• Christian DA, Hunter CA. 2012. Particle-mediated delivery of cytokines for immunotherapy. Immunotherapy. 4(4):425–41.
   PubMed Web of Science ®Google Scholar
• Chung AY, Li Q, Blair SJ, De Jesus M, Dennis KL, LeVea C, Yao J, Sun Y, Conway TF, Virtuoso LP, et al. 2014. Oral interleukin-10 alleviates polyposis via neutralization of pathogenic T-regulatory cells. Cancer Res. 74(19):5377–85.
   PubMed Web of Science ®Google Scholar
• Cleland JL, Jones AJ. 1996. Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres. Pharm Res. 13(10):1464–75.
   PubMed Web of Science ®Google Scholar
• Conway TF, Hammer L, Furtado S, Mathiowitz E, Nicoletti F, Mangano K, Egilmez NK, Auci DL. 2015. Oral delivery of particulate transforming growth factor beta 1 and all-trans retinoic acid reduces gut inflammation in murine models of inflammatory bowel disease. J Crohns Colitis. 9(8):647–58.
   PubMed Web of Science ®Google Scholar
• De Leede LG, Humphries JE, Bechet AC, Van Hoogdalem EJ, Verrijk R, Spencer DG. 2008. Novel controlled-release lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial. J Interferon Cytokine Res. 28(2):113–22.
   PubMed Web of Science ®Google Scholar
• DeFail AJ, Chu CR, Izzo N, Marra KG. 2006. Controlled release of bioactive TGF-beta 1 from microspheres embedded within biodegradable hydrogels. Biomaterials. 27(8):1579–85.
   PubMed Web of Science ®Google Scholar
• Devrim B, Bozkir A, Canefe K. 2011. Preparation and evaluation of poly(lactic-co-glycolic acid) microparticles as a carrier for pulmonary delivery of recombinant human interleukin-2: II. In vitro studies on aerodynamic properties of dry powder inhaler formulations. Drug Dev Ind Pharm. 37(11):1376–86.
   PubMed Web of Science ®Google Scholar
• Digiusto D.L, Melsop K, Srivastava R, Tran C-A.. 2018. Proceedings of the first academic symposium on developing, qualifying and operating a cell and gene therapy manufacturing facility. Cytotherapy. 20:1486–1494. doi: 10.1016/j.jcyt.2018.07.008.
   Google Scholar
• Diwan M, Park TG. 2003. Stabilization of recombinant interferon-alpha by pegylation for encapsulation in PLGA microspheres. Int J Pharm. 252(1–2):111–22.
   PubMed Web of Science ®Google Scholar
• Duncan SA, Dixit S, Sahu R, Martin D, Baganizi DR, Nyairo E, Villinger F, Singh SR, Dennis VA. 2019. prolonged release and functionality of interleukin-10 encapsulated within PLA-PEG nanoparticles. Nanomaterials. 9(8):1074–79.
   Web of Science ®Google Scholar
• Dzyublyk I, Yegorova T, Moroz L, Popovych O, Zaytsev I, Miroshnichenko V, Kromminga A, Wilkes MM, van Hoogdalem EJ, Humphries JE. 2011. Controlled release recombinant human interferon-alpha2b for treating patients with chronic hepatitis C genotype 1: a phase 2a clinical trial. J Viral Hepat. 18(4):271–79.
   PubMed Web of Science ®Google Scholar
• Egilmez NK, Jong YS, Hess SD, Jacob JS, Mathiowitz E, Bankert RB. 2000b. Cytokines delivered by biodegradable microspheres promote effective suppression of human tumors by human peripheral blood lymphocytes in the SCID-Winn model. J Immunother. 23(2):190–95.
   PubMed Web of Science ®Google Scholar
• Egilmez NK, Jong YS, Iwanuma Y, Jacob JS, Santos CA, Chen FA, Mathiowitz E, Bankert RB. 1998. Cytokine immunotherapy of cancer with controlled release biodegradable microspheres in a human tumor xenograft/SCID mouse model. Cancer Immunol Immunother. 46(1):21–24.
   PubMed Web of Science ®Google Scholar
• Egilmez NK, Jong YS, Sabel MS, Jacob JS, Mathiowitz E, Bankert RB. 2000a. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res. 60(14):3832–37.
   PubMed Web of Science ®Google Scholar
• Gerber SA, Lim JY, Connolly KA, Sedlacek AL, Barlow ML, Murphy SP, Egilmez NK, Lord EM. 2014. Radio-responsive tumors exhibit greater intratumoral immune activity than nonresponsive tumors. Int J Cancer. 134(10):2383–92.
   PubMed Web of Science ®Google Scholar
• Golumbek PT, Azhari R, Jaffee EM, Levitsky HI, Lazenby A, Leong K, Pardoll DM. 1993. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res. 53(24):5841–44.
   PubMed Web of Science ®Google Scholar
• Gu T, De Jesus M, Gallagher HC, Burris TP, Egilmez NK. 2017. Oral IL-10 suppresses colon carcinogenesis via elimination of pathogenicCD4(+) T-cells and induction of antitumor CD8(+) T-cell activity. Oncoimmunology. 6(6):e1319027.
   PubMed Web of Science ®Google Scholar
• Gu T, Kilinc MO, Egilmez NK. 2008. Transient activation of tumor-associated T-effector/memory cells promotes tumor eradication via NK-cell recruitment: minimal role for long-term T-cell immunity in cure of metastatic disease. Cancer Immunol Immunother. 57(7):997–1005.
   PubMed Web of Science ®Google Scholar
• Gu T, Rowswell-Turner RB, Kilinc MO, Egilmez NK. 2010. Central role of IFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunity. Cancer Res. 70(1):129–38.
   PubMed Web of Science ®Google Scholar
• Ha SJ, Park SH, Kim HJ, Kim SC, Kang HJ, Lee EG, Kwon SG, Kim BM, Lee SH, Kim WB, et al. 2006. Enhanced immunogenicity and protective efficacy with the use of interleukin-12-encapsulated microspheres plus AS01B in tuberculosis subunit vaccination. Infect Immun. 74(8):4954–59.
   PubMed Web of Science ®Google Scholar
• Hanes J, Sills A, Zhao Z, Suh KW, Tyler B, DiMeco F, Brat DJ, Choti MA, Leong KW, Pardoll DM, et al. 2001. Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm Res. 18(7):899–906.
   PubMed Web of Science ®Google Scholar
• Harden JL, Gu T, Kilinc MO, Rowswell-Turner RB, Virtuoso LP, Egilmez NK. 2011. Dichotomous effects of IFN-gamma on dendritic cell function determine the extent of IL-12-driven antitumor T cell immunity. J Immunol. 187(1):126–32.
   PubMed Web of Science ®Google Scholar
• Hess SD, Egilmez NK, Bailey N, Anderson TM, Mathiowitz E, Bernstein SH, Bankert RB. 2003. Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-gamma. J Immunol. 170(1):400–12.
   PubMed Web of Science ®Google Scholar
• Hill HC, Conway TF Jr., Sabel MS, Jong YS, Mathiowitz E, Bankert RB, Egilmez NK. 2002. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res. 62(24):7254–63.
   PubMed Web of Science ®Google Scholar
• Hong H, Jo JR, Yeon JH, Hong JT, Jung KH, Yoo SK, Jang BC. 2011. Preparation of branched dextran microspheres of soluble interferon-alpha and its activity in vitro and in vivo. J Microbiol Biotechnol. 21(2):176–82.
   PubMed Web of Science ®Google Scholar
• Hong L, Tabata Y, Miyamoto S, Yamada K, Aoyama I, Tamura M, Hashimoto N, Ikada Y. 2000. Promoted bone healing at a rabbit skull gap between autologous bone fragment and the surrounding intact bone with biodegradable microspheres containing transforming growth factor-beta1. Tissue Eng. 6(4):331–40.
   PubMedGoogle Scholar
• Hora MS, Rana RK, Nunberg JH, Tice TR, Gilley RM, Hudson ME. 1990. Controlled release of interleukin-2 from biodegradable microspheres. Biotechnology (N Y). 8(8):755–58.
   PubMedGoogle Scholar
• Hsu W, Lesniak MS, Tyler B, Brem H. 2005. Local delivery of interleukin-2 and adriamycin is synergistic in the treatment of experimental malignant glioma. J Neurooncol. 74(2):135–40.
   PubMed Web of Science ®Google Scholar
• Kawamura I, Takemura G, Tsujimoto A, Watanabe T, Kanamori H, Esaki M, Kobayashi H, Takeyama T, Kawaguchi T, Goto K, et al. 2011. Treatment of leg ischemia with biodegradable gelatin hydrogel microspheres incorporating granulocyte colony-stimulating factor. J Cardiovasc Pharmacol. 57(4):416–23.
   PubMed Web of Science ®Google Scholar
• Kilinc MO, Aulakh KS, Nair RE, Jones SA, Alard P, Kosiewicz MM, Egilmez NK. 2006. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. J Immunol. 177(10):6962–73.
   PubMed Web of Science ®Google Scholar
• Kilinc MO, Gu T, Harden JL, Virtuoso LP, Egilmez NK. 2009a. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity. J Immunol. 182(7):4217–25.
   PubMed Web of Science ®Google Scholar
• Kilinc MO, Rowswell-Turner RB, Gu T, Virtuoso LP, Egilmez NK. 2009b. Activated CD8+ T-effector/memory cells eliminate CD4+ CD25+ Foxp3+ T-suppressor cells from tumors via FasL mediated apoptosis. J Immunol. 183(12):7656–60.
   PubMed Web of Science ®Google Scholar
• Kojima K, Ignotz RA, Kushibiki T, Tinsley KW, Tabata Y, Vacanti CA. 2004. Tissue-engineered trachea from sheep marrow stromal cells with transforming growth factor beta2 released from biodegradable microspheres in a nude rat recipient. J Thorac Cardiovasc Surg. 128(1):147–53.
   PubMed Web of Science ®Google Scholar
• Koten JW, Van Luyn MJ, Cadee JA, Brouwer L, Hennink WE, Bijleveld C, Den Otter W. 2003. IL-2 loaded dextran microspheres with attractive histocompatibility properties for local IL-2 cancer therapy. Cytokine. 24(3):57–66.
   PubMed Web of Science ®Google Scholar
• Kudva AK, Dikina AD, Luyten FP, Alsberg E, Patterson J. 2019. Gelatin microspheres releasing transforming growth factor drive in vitro chondrogenesis of human periosteum derived cells in micromass culture. Acta Biomater. 90:287–99.
   PubMed Web of Science ®Google Scholar
• Kuriakose MA, Chen FA, Egilmez NK, Jong YS, Mathiowitz E, DeLacure MD, Hicks WL Jr., Loree TL, Bankert RB. 2000. Interleukin-12 delivered by biodegradable microspheres promotes the antitumor activity of human peripheral blood lymphocytes in a human head and neck tumor xenograft/SCID mouse model. Head Neck. 22(1):57–63.
   PubMed Web of Science ®Google Scholar
• Lagarce F, Garcion E, Faisant N, Thomas O, Kanaujia P, Menei P, Benoit JP. 2006. Development and characterization of interleukin-18-loaded biodegradable microspheres. Int J Pharm. 314(2):179–88.
   PubMedGoogle Scholar
• Li Q, Anderson CD, Egilmez NK. 2018. Inhaled IL-10 suppresses lung tumorigenesis via abrogation of inflammatory macrophage-Th17 cell axis. J Immunol. 201(9):2842–50.
   PubMed Web of Science ®Google Scholar
• Lim SJ, Park MK, Um SW, Yoon HY, Ryu JH, Lim D-K, Kim K. 2019. Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy. Theranostics. 9(25):7906–23.
   PubMed Web of Science ®Google Scholar
• Liu Y, Egilmez NK, Russell MW. 2013. Enhancement of adaptive immunity to Neisseria gonorrhoeae by local intravaginal administration of microencapsulated interleukin 12. J Infect Dis. 208(11):1821–29.
   PubMed Web of Science ®Google Scholar
• Liu Y, Hammer LA, Liu W, Hobbs MM, Zielke RA, Sikora AE, Jerse AE, Egilmez NK, Russell MW. 2017. Experimental vaccine induces Th1-driven immune responses and resistance to Neisseria gonorrhoeae infection in a murine model. Mucosal Immunol. 10(6):1594–608.
   PubMed Web of Science ®Google Scholar
• Liu Y, Perez J, Hammer LA, Gallagher HC, De Jesus M, Egilmez NK, Russell MW. 2018. Intravaginal administration of interleukin 12 during genital gonococcal infection in mice induces immunity to heterologous strains of Neisseria gonorrhoeae. mSphere. 3:1.
   Web of Science ®Google Scholar
• Maysinger D, Berezovskaya O, Fedoroff S. 1996. The hematopoietic cytokine colony stimulating factor 1 is also a growth factor in the CNS: (II). Microencapsulated CSF-1 and LM-10 cells as delivery systems. Exp Neurol. 141(1):47–56.
   PubMed Web of Science ®Google Scholar
• Mills BN, Connolly KA, Ye J, Murphy JD, Uccello TP, Han BJ, Zhao T, Drage MG, Murthy A, Qiu H, et al. 2019. Stereotactic body radiation and interleukin-12 combination therapy eradicates pancreatic tumors by repolarizing the immune microenvironment. Cell Rep. 29(2):406–421 e5.
   PubMed Web of Science ®Google Scholar
• Mullerad J, Cohen S, Voronov E, Apte RN. 2000. Macrophage activation for the production of immunostimulatory cytokines by delivering interleukin 1 via biodegradable microspheres. Cytokine. 12(11):1683–90.
   PubMed Web of Science ®Google Scholar
• Nair RE, Jong YS, Jones SA, Sharma A, Mathiowitz E, Egilmez NK. 2006a. IL-12 + GM-CSF microsphere therapy induces eradication of advanced spontaneous tumors in her-2/neu transgenic mice but fails to achieve long-term cure due to the inability to maintain effector T-cell activity. J Immunother. 29(1):10–20.
   PubMed Web of Science ®Google Scholar
• Nair RE, Kilinc MO, Jones SA, Egilmez NK. 2006b. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors. J Immunol. 176(12):7325–34.
   PubMed Web of Science ®Google Scholar
• Nakase H, Okazaki K, Tabata Y, Ozeki M, Watanabe N, Ohana M, Uose S, Uchida K, Nishi T, Mastuura M, et al. 2002. New cytokine delivery system using gelatin microspheres containing interleukin-10 for experimental inflammatory bowel disease. J Pharmacol Exp Ther. 301(1):59–65.
   PubMed Web of Science ®Google Scholar
• Oft M. 2014. IL-10: master switch from tumor-promoting inflammation to antitumor immunity. Cancer Immunol Res. 2(3):194–99.
   PubMed Web of Science ®Google Scholar
• Otto DPA, de Villiers MM. 2015. Differences in physicochemical properties to consider in the design, evaluation and choice between microparticles and nanoparticles for drug delivery. Expert Opin Drug Delivery. 12(5):763–77.
   PubMed Web of Science ®Google Scholar
• Ozbas-Turan S, Akbuga J, Aral C. 2002. Controlled release of interleukin-2 from chitosan microspheres. J Pharm Sci. 91(5):1245–51.
   PubMed Web of Science ®Google Scholar
• Park E, Hart ML, Rolauffs B, Stegemann JP, Annamalai TR. 2020. Bioresponsive microspheres for on-demand delivery of anti-inflammatory cytokines for articular cartilage repair. J Biomed Mater Res A. 108(3):722–33.
   PubMed Web of Science ®Google Scholar
• Peter SJ, Lu L, Kim DJ, Stamatas GN, Miller MJ, Yaszemski MJ, Mikos AG. 2000. Effects of transforming growth factor beta1 released from biodegradable polymer microparticles on marrow stromal osteoblasts cultured on poly(propylene fumarate) substrates. J Biomed Mater Res. 50(3):452–62.
   PubMed Web of Science ®Google Scholar
• Rhines LD, Sampath P, DiMeco F, Lawson HC, Tyler BM, Hanes J, Olivi A, Brem H. 2003. Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma. Neurosurgery. 52(4):872–79; discussion 879–80. doi:10.1227/01.neu.0000053211.39087.d1.
   PubMed Web of Science ®Google Scholar
• Rowswell-Turner RB, Harden JL, Nair RE, Gu T, Kilinc MO, Egilmez NK. 2011. Chronic chemoimmunotherapy achieves cure of spontaneous murine mammary tumors via persistent blockade of posttherapy counter-regulation. J Immunol. 187(8):4109–18.
   PubMed Web of Science ®Google Scholar
• Sabel MS, Arora A, Su G, Griffith KA, Mathiowitz E, Reineke JJ, Chang AE. 2007a. Generation of a tumor-specific systemic response after intratumoral injection of IL-12 and IL-18-loaded polylactic acid microspheres. J Immunother. 30(8):808–16.
   PubMed Web of Science ®Google Scholar
• Sabel MS, Arora A, Su G, Mathiowitz E, Reineke JJ, Chang AE. 2007b. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells. Surgery. 142(5):749–60.
   PubMed Web of Science ®Google Scholar
• Sabel MS, Hill H, Jong YS, Mathiowitz E, Bankert RB, Egilmez NK. 2001. Neoadjuvant therapy with interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant metastases. Surgery. 130(3):470–78.
   PubMed Web of Science ®Google Scholar
• Sabel MS, Skitzki J, Stoolman L, Egilmez NK, Mathiowitz E, Bailey N, Chang WJ, Chang AE. 2004. Intratumoral IL-12 and TNF-alpha-loaded microspheres lead to regression of breast cancer and systemic antitumor immunity. Ann Surg Oncol. 11(2):147–56.
   PubMed Web of Science ®Google Scholar
• Sabel MS, Su G, Griffith KA, Chang AE. 2010. Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer. Breast Cancer Res Treat. 122(2):325–36.
   PubMed Web of Science ®Google Scholar
• Saez V, Ramon J, Peniche C, Hardy E. 2012. Microencapsulation of alpha interferons in biodegradable microspheres. J Interferon Cytokine Res. 32(7):299–311.
   PubMed Web of Science ®Google Scholar
• Sanchez A, Tobio M, Gonzalez L, Fabra A, Alonso MJ. 2003. Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha. Eur J Pharm Sci. 18(3–4):221–29.
   PubMed Web of Science ®Google Scholar
• Shah AU, D’Souza MJ. 1999. Sustained-release interleukin-12 microspheres in the treatment of cancer. Drug Dev Ind Pharm. 25(9):995–1004.
   PubMed Web of Science ®Google Scholar
• Sharma A, Harper CM, Hammer L, Nair RE, Mathiowitz E, Egilmez NK. 2004. Characterization of cytokine-encapsulated controlled-release microsphere adjuvants. Cancer Biother Radiopharm. 19(6):764–69.
   PubMed Web of Science ®Google Scholar
• Sinha VR, Trehan A. 2003. Biodegradable microspheres for protein delivery. J Controlled Release. 90(3):261–80.
   PubMed Web of Science ®Google Scholar
• Solorio LD, Vieregge EL, Dhami CD, Dang PN, Alsberg E. 2012. Engineered cartilage via self-assembled hMSC sheets with incorporated biodegradable gelatin microspheres releasing transforming growth factor-beta1. J Controlled Release. 158(2):224–32.
   PubMed Web of Science ®Google Scholar
• Sugiyama Y, Kato M, Chen FA, Williams SS, Kawaguchi Y, Miya K, Jong YS, Mathiowitz E, Egilmez NK, Bankert RB. 2001. Human inflammatory cells within the tumor microenvironment of lung tumor xenografts mediate tumor growth suppression in situ that depends on and is augmented by interleukin-12. J Immunother. 24(1):37–45.
   PubMed Web of Science ®Google Scholar
• Truong-Le V, Lovalenti PM, Abdul-Fattah AM. 2015. Stabilization challenges and formulation strategies associated with oral biologic drug delivery systems. Adv Drug Delivery Rev. 93:95–108.
   PubMed Web of Science ®Google Scholar
• van der Walle CF, Sharma G, Ravi Kumar M. 2009. Current approaches to stabilising and analysing proteins during microencapsulation in PLGA. Expert Opin Drug Delivery. 6(2):177–86.
   PubMed Web of Science ®Google Scholar
• Watkins SK, Egilmez NK, Suttles J, Stout RD. 2007. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J Immunol. 178(3):1357–62.
   PubMed Web of Science ®Google Scholar
• Yang J, Cleland JL. 1997. Factors affecting the in vitro release of recombinant human interferon-gamma (rhIFN-gamma) from PLGA microspheres. J Pharm Sci. 86(8):908–14.
   PubMed Web of Science ®Google Scholar
• Zhang YM, Yang F, Yang YQ, Song FL, Xu AL. 2008. Recombinant interferon-alpha2b poly(lactic-co-glycolic acid) microspheres: pharmacokinetics-pharmacodynamics study in rhesus monkeys following intramuscular administration. Acta Pharmacol Sin. 29(11):1370–75.
   PubMed Web of Science ®Google Scholar
• Zhao H, Wu F, Cai Y, Chen Y, Wei L, Liu Z, Yuan W. 2013. Local antitumor effects of intratumoral delivery of rlL-2 loaded sustained-release dextran/PLGA-PLA core/shell microspheres. Int J Pharm. 450(1–2):235–40.
   PubMedGoogle Scholar
• Zheng CH, Yu HY, Gao JQ, Sun XY, Liang WQ. 2008. Hydrophilic biodegradable microspheres of interferon-alpha and its pharmacokinetics in mice. J Biomed Mater Res B Appl Biomater. 85(1):225–30.
   PubMedGoogle Scholar
• Zhou S, Deng X, He S, Li X, Jia W, Wei D, Zhang Z, Ma J. 2002. Study on biodegradable microspheres containing recombinant interferon-alpha-2a. J Pharm Pharmacol. 54(9):1287–92.
   PubMed Web of Science ®Google Scholar
• Zhou S, Sun J, Sun L, Dai Y, Liu L, Li X, Wang J, Weng J, Jia W, Zhang Z. 2008. Preparation and characterization of interferon-loaded magnetic biodegradable microspheres. J Biomed Mater Res B Appl Biomater. 87(1):189–96.
   PubMedGoogle Scholar